| Type | Title | Date Released | |
|---|---|---|---|
8-K | Zura Bio Announces Phase 2 TibuSHIELD Study Results in Hidradenitis Suppurativa and Provides Clinical Pipeline Update New | ||
EFFECT | Form EFFECT | ||
S-3 | October 2026 SHELF + ATM EFFECTIVE, DATED 2026-11-03 | ||
8-K | Zura Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Updates | ||
10-Q | Form 10-Q | ||
S-8 | Form S-8 | ||
144 | Form 144 | ||
144 | Form 144 | ||
8-K | Zura Bio Corporate Overview: Advancing Tibulizumab for Immune-Mediated Diseases | ||
144 | Form 144 | ||
144 | Form 144 | ||
8-K | Zura Bio Reports Second Quarter 2026 Financial Results and Corporate Updates |
